These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 11323200)

  • 1. Methodological approaches to the population analysis of toxicity data.
    Aarons L; Graham G
    Toxicol Lett; 2001 Mar; 120(1-3):405-10. PubMed ID: 11323200
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Significance of ICH--toxicokinetics guidance and its practice--a useful approach for safety drug development].
    Tsuda M; Ohno Y
    Kokuritsu Iyakuhin Shokuhin Eisei Kenkyusho Hokoku; 1997; (115):1-14. PubMed ID: 9641814
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sparse sampling for assessment of drug exposure in toxicological studies.
    Burtin P; Mentre F; van Bree J; Steimer JL
    Eur J Drug Metab Pharmacokinet; 1996; 21(2):105-11. PubMed ID: 8839683
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and nutritional assessment of GM plants and derived food and feed: the role of animal feeding trials.
    EFSA GMO Panel Working Group on Animal Feeding Trials
    Food Chem Toxicol; 2008 Mar; 46 Suppl 1():S2-70. PubMed ID: 18328408
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The impact of composite AUC estimates on the prediction of systemic exposure in toxicology experiments.
    Sahota T; Danhof M; Della Pasqua O
    J Pharmacokinet Pharmacodyn; 2015 Jun; 42(3):251-61. PubMed ID: 25868863
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Modelling and simulation of variability and uncertainty in toxicokinetics and pharmacokinetics.
    Nestorov I
    Toxicol Lett; 2001 Mar; 120(1-3):411-20. PubMed ID: 11323201
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Assessing drug exposure in rodent toxicity studies without satellite animals.
    Nedelman JR; Gibiansky E; Tse FL; Babiuk C
    J Pharmacokinet Biopharm; 1993 Jun; 21(3):323-34. PubMed ID: 8258771
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of repeated micro and macro blood sampling on clinical chemistry and haematology in rats for toxicokinetic studies.
    Karp NA; Coleman L; Cotton P; Powles-Glover N; Wilson A
    Regul Toxicol Pharmacol; 2023 Jun; 141():105386. PubMed ID: 37085139
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacometrics: modelling and simulation tools to improve decision making in clinical drug development.
    Gieschke R; Steimer JL
    Eur J Drug Metab Pharmacokinet; 2000; 25(1):49-58. PubMed ID: 11032091
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Applications of population approaches in toxicology.
    Bois FY
    Toxicol Lett; 2001 Mar; 120(1-3):385-94. PubMed ID: 11323198
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Implementing Toxicity Testing in the 21st Century (TT21C): Making safety decisions using toxicity pathways, and progress in a prototype risk assessment.
    Adeleye Y; Andersen M; Clewell R; Davies M; Dent M; Edwards S; Fowler P; Malcomber S; Nicol B; Scott A; Scott S; Sun B; Westmoreland C; White A; Zhang Q; Carmichael PL
    Toxicology; 2015 Jun; 332():102-11. PubMed ID: 24582757
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Toxicokinetics and physiologically based toxicokinetics in toxicology and risk assessment.
    Dixit R; Riviere J; Krishnan K; Andersen ME
    J Toxicol Environ Health B Crit Rev; 2003; 6(1):1-40. PubMed ID: 12587252
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Precision of estimates of an ADI (or TDI or PTWI).
    Speijers GJ
    Regul Toxicol Pharmacol; 1999 Oct; 30(2 Pt 2):S87-93. PubMed ID: 10597619
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Model-based analysis of thromboxane B₂ and prostaglandin E₂ as biomarkers in the safety evaluation of naproxen.
    Sahota T; Sanderson I; Danhof M; Della Pasqua O
    Toxicol Appl Pharmacol; 2014 Aug; 278(3):209-19. PubMed ID: 24667227
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacology-based toxicity assessment: towards quantitative risk prediction in humans.
    Sahota T; Danhof M; Della Pasqua O
    Mutagenesis; 2016 May; 31(3):359-74. PubMed ID: 26970519
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The use of in vitro data in risk assessment.
    Bernauer U; Oberemm A; Madle S; Gundert-Remy U
    Basic Clin Pharmacol Toxicol; 2005 Mar; 96(3):176-81. PubMed ID: 15733212
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serial versus sparse sampling in toxicokinetic studies.
    Tse FL; Nedelman JR
    Pharm Res; 1996 Jul; 13(7):1105-8. PubMed ID: 8842053
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Advantages of toxicokinetics in new drug development.
    Horii I
    Toxicol Lett; 1998 Dec; 102-103():657-64. PubMed ID: 10022331
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Toxicokinetics in preclinical evaluation.
    Baldrick P
    Drug Discov Today; 2003 Feb; 8(3):127-33. PubMed ID: 12568782
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Concomitant toxicokinetics: techniques for and interpretation of exposure data obtained during the conduct of toxicology studies.
    Dahlem AM; Allerheiligen SR; Vodicnik MJ
    Toxicol Pathol; 1995; 23(2):170-8. PubMed ID: 7569672
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.